TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about the TULIP long term extension study and its safety findings at 3 years.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study‘ (Abstract number: 1652) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is the rationale for the use of anifrolumab in the treatment of patients with systemic lupus erythematosus (SLE)? (0:16)
- What did the TULIP-1 and TULIP-2 clinical trials teach us about the efficacy and safety of anifrolumab in the treatment of moderate to severe SLE? (0:47)
- Could you tell us a little about the TULIP long term extension study and its findings at 3 years? (3:50)
- What are the implications of these findings for the future clinical use of anifrolumab in this indication? (5:48)
Disclosures: Kevin Winthrop discloses consulting for Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca, and Novartis; and receiving grant/ research support from BMS and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
